Cepheid's Q3 Revenues Fall 7 Percent on Lower Systems Sales; Beat Estimates | GenomeWeb

NEW YORK (GenomeWeb News) – Cepheid reported after the close of the market Wednesday that its third-quarter revenues declined 7 percent as its total systems sales fell 24 percent year over year.

The Sunnyvale, Calif.-based molecular diagnostics firm generated total revenues of $41.6 million for the three-month period ended Sept. 30, compared to $44.9 million for the third quarter of 2008. Its results beat analysts' consensus estimate of $40.9 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.